Aadi Bioscience (NASDAQ:AADI) Given Neutral Rating at HC Wainwright

Aadi Bioscience (NASDAQ:AADIGet Free Report)‘s stock had its “neutral” rating restated by equities researchers at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports.

Aadi Bioscience Stock Up 5.1 %

Shares of Aadi Bioscience stock opened at $1.87 on Tuesday. Aadi Bioscience has a fifty-two week low of $1.55 and a fifty-two week high of $8.60. The business’s fifty day moving average is $2.05 and its two-hundred day moving average is $2.67. The firm has a market cap of $45.91 million, a PE ratio of -0.73 and a beta of 0.64.

Aadi Bioscience (NASDAQ:AADIGet Free Report) last released its earnings results on Wednesday, March 13th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.67) by $0.07. The firm had revenue of $6.33 million for the quarter, compared to the consensus estimate of $6.46 million. Aadi Bioscience had a negative return on equity of 61.83% and a negative net margin of 288.72%. Equities research analysts anticipate that Aadi Bioscience will post -2.48 EPS for the current year.

Insider Buying and Selling

In related news, Chairman Neil Desai sold 27,036 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $1.97, for a total value of $53,260.92. Following the transaction, the chairman now directly owns 1,426,507 shares of the company’s stock, valued at approximately $2,810,218.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last quarter, insiders sold 99,772 shares of company stock valued at $202,939. Insiders own 35.80% of the company’s stock.

Institutional Investors Weigh In On Aadi Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. TD Asset Management Inc lifted its stake in shares of Aadi Bioscience by 100.0% in the 3rd quarter. TD Asset Management Inc now owns 48,166 shares of the company’s stock valued at $233,000 after purchasing an additional 24,083 shares in the last quarter. Marquette Asset Management LLC purchased a new position in Aadi Bioscience in the first quarter valued at approximately $135,000. Finally, Decheng Capital LLC acquired a new position in Aadi Bioscience during the fourth quarter valued at approximately $1,063,000. 52.08% of the stock is currently owned by institutional investors and hedge funds.

About Aadi Bioscience

(Get Free Report)

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.

Read More

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.